Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication April 7, 2017
- Accepted for publication April 26, 2017
- Published online September 1, 2017.
Copyright & Usage
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- 1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
- 2Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland; and
- 3Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
- For correspondence or reprints contact: Damian Wild, Division of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. E-mail: damian.wild{at}usb.ch
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
- 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
- The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?
- Targeted {alpha}-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
- Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
- Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
- Revisiting Weight-Normalized SUV and Lean-Body-Mass-Normalized SUV in PET Studies
- Training Requirements for Theranostics: A Unique Opportunity for Collaboration
- Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro
- New Developments in Peptide Receptor Radionuclide Therapy
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- Theranostic Concepts: More Than Just a Fashion Trend--Introduction and Overview